Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 343 followers
Latest posts
Last updated about 7 hours ago
Abbott garners FDA nod for its TactiFlex catheter to treat AFib
about 7 hours ago
Abbot received FDA clearance for its latest-generation catheter that allows physicians more...
Luma locks down 15-year, $410M fund for life science investments
about 9 hours ago
Luma Group announced the final close of its inaugural life sciences venture...
Google-backed Encoded gains $275M to advance Dravet drug, scale genetic med manufacturing
about 9 hours ago
Neuro-focused Encoded Therapeutics has bagged a $275 million series F round to...
Kura creates Lilly-backed spinout armed with $50M to advance next-gen diabetes therapy
about 9 hours ago
Kura Oncology has spun out a biotech armed with $50 million in...
Tyra rolls toward pivotal bladder cancer study even as midphase data deflates stock
about 10 hours ago
Tyra Biosciences has reported initial phase 2 data on dabogratinib in bladder...
FDA solidifies CDER, CBER leadership posts as commissioner confirmation awaits
about 10 hours ago
In a stabilizing move, the Department of Health and Human Services announced...
Labcorp snaps up MLM Medical Labs to boost laboratory footprint
about 10 hours ago
Medtech and testing giant Labcorp has bought out MLM Medical Labs to...
Solstice rises with $225M series A to advance next-gen CTLA-4 immunotherapy into phase 2
about 12 hours ago
Solstice Oncology has secured $225 million in series A funds to advance...
Schrödinger births new immunology and inflammation biotech, Tectora Therapeutics
about 12 hours ago
Schrödinger announced the launch of new immune disease-focused Tectora Therapeutics, which comes...
Beeline flies into phase 3 as oral lupus drug soars past placebo
about 12 hours ago
A phase 2 trial of Beeline Medicines’ afimetoran has hit its primary...
Evommune gives up hope for MRGPRX2 antagonist to treat itch after latest phase 2 fail
about 14 hours ago
Evommune’s MRGPRX2 antagonist has flunked another phase 2 trial, wiping out the...
Boston Scientific cyberattack likely to have ‘material impact’ on financial results
1 day ago
The recent cyberattack on Boston Scientific is looking more serious than the...